Safety Study of Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered With Other Pediatric Vaccines to Healthy Toddlers

Trial Profile

Safety Study of Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered With Other Pediatric Vaccines to Healthy Toddlers

Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Hepatitis A vaccine inactivated; Measles mumps and rubella virus vaccine; MMR-varicella zoster virus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate; Varicella zoster virus vaccine live
  • Indications Hepatitis A; Measles; Meningococcal infections; Mumps; Rubella
  • Focus Adverse reactions; Registrational
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 08 Nov 2012 Pivotal clinical trial data has been published in the Pediatric Infectious Disease Journal, according to a Sanofi Pasteur media release.
    • 01 Nov 2012 Results published in the Pediatric Infectious Disease Journal.
    • 22 Apr 2011 Based in part on the results from this trial, the US FDA approved Menactra for use in infants aged 9-23 months of age, for the prevention of invasive meningococcal disease caused by serogroups A, C, Y and W-135.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top